Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 6
• Langue: English

Extrait

Frost & Sullivan: Launch of New Classes of

Oral Antidiabetic Drugs by 2014 will Uplift

Prospects for the European Diabetes

Therapeutics Market

PR Newswire

LONDON, June 25, 2012

- Long-acting Insulins Poised to Grab a Large Share of the Market in

the Future

LONDON

,

June 25, 2012

/PRNewswire/ -- The alarming prevalence rate of

diabetes and its significant growth over the last year has encouraged market

participants in the pharmaceuticals industry to venture into the burgeoning

diabetics therapeutics segment. With a slew of effective formulations in the

pipeline, competition in the market will be turned up a few notches.

New analysis from Frost & Sullivan (http://www.pharma.frost.com),

European

Diabetes Therapeutics Market

, finds that the market earned revenues of

approximately

$8.60 billion

in 2010 and estimates this to reach approximately

$13.97 billion

in 2017 at a compound annual growth rate (CAGR) of 7.2 per cent

from 2010-2017.

"In 2010, the incidence of diabetes was highest in

Germany

, with approximately

7.4 million patients, followed by

France

,

Italy

and

Spain

," says Frost & Sullivan

Research Analyst K. Srinivas Sashidhar. "According to International Diabetes

Federation (IDF) data, the prevalence is going to accelerate by 2030 and is

estimated to increase in small regions such as the Benelux and Scandinavia."

The insulin market is dominated by modern insulins and analogues. Long-acting

insulins are expected to have a large market in the future. New therapeutic

classes of drugs are expected to be a major contributor to the OAD segment.

The expense for diabetes treatment has become a global burden, especially for

the middle- and low-income groups. Participants in this space are battling

pricing pressures; however, high levels of competition, improved therapies, and

the introduction of biosimilars will help deal with this issue.

Major concerns surrounding drug safety and side effects have created cause

for concern among participants. This factor will have an impact on the global

market in the near future, considering the need for compliance with strict

European Medicines Agency and Food and Drug Administration (FDA)

guidelines. These issues have alarmed medicines agencies to have strict control

over efficacy and safety data. As new types of products emerge in the market,

safety issues are bound to have a high impact in the future.

To ensure market progression, it is vital to build awareness on disease

management. Participants need access to an interdisciplinary healthcare team

that must be alert to new innovations to help develop treatment plans. It is also

essential to drive home the importance of diet and exercise to patients.

"New kinds of therapeutic classes, GLP-1s, and new combination therapies will

take market prospects forward," says Sashidhar. "Metformin will continue to be

a strong competing product in

Europe

."

If you are interested in more information on this study, please send an e-mail to